Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1998-11-23
2000-03-07
Jordan, Kimberly
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514258, 514322, 514327, 514661, A61K 3154, A61K 31505, A61K 31445, A61K 3113
Patent
active
060340797
ABSTRACT:
Nicotine-responsive neuropsychiatric disorders can be treated by administering a nicotine antagonist, particularly mecamylamine. Combination therapy of mecamylamine with a neuroleptic drug also is disclosed. The neuropsychiatric disorders include Tourette's syndrome, schizophrenia, depression, bipolar disorder, tremors, attention deficit hyperactivity disorder, obsessive-compulsive disorder, hemidystonia, rage outbursts and tardive dyskinesia.
REFERENCES:
patent: 2831027 (1958-04-01), Pfister, III et al.
patent: 2894987 (1959-07-01), Gustav et al.
patent: 3148118 (1964-09-01), Thesing et al.
patent: 3164601 (1965-01-01), Thesing et al.
patent: 4837218 (1989-06-01), Olney
patent: 4891380 (1990-01-01), Wiiliams et al.
patent: 5554610 (1996-09-01), Williams et al.
patent: 5574052 (1996-11-01), Rose et al.
patent: 5583140 (1996-12-01), Bencherif et al.
patent: 5691365 (1997-11-01), Crooks et al.
patent: 5859004 (1999-01-01), Olesen
Shieh, et al. (1996) Biology of Reproduction, vol. 54, May, pp. 987-992 Sexual Differences in the Diurnal Changes . . . of Neuron Activity in Rat: Role of Cholinergic Control.
Sano Coporation website (1997).
Shytle, et al. (1996) Drug Development Research, vol. 38, pp. 290-298 "Transdermal Nicotine for Tourett's Syndrome".
(1989) The Merk Index, p. 905 "5654. Mecamylamine".
Stone, et al. (1962) Journal of Medicine & Pharm. Chemistry, vol. 5(4), pp. 665-690 "Chemistry and Structure-Activity Relationship of Mecamylamine and Derivatives".
Seumaru, et al.; Naonyn-Schmledeberg's Arch pharmacol (1994) 350:153-157 "Characteristics of tail-tremor induced by nicotine in rats".
Psychopharmacologia (Berl.) 46, 119-121 (1976) "Nicotine-Like . . . after . . . Mecamylamine in . . . rats".
Pharmacol Ther, vol. 74, No. 1, pp. 21-25, 1997 "Nicotine for the Treatment of Tourette's Syndrome".
Shytle, et al; Int'l Weekly Journal of Science, vol. 384, pp. 18-19 "Nicotine, tabacco and Addiction" (1997).
Sanberg, et al.; pp. 35-41 (1997) "Nicotine as a Therapeutic Adjunct for Tourett's Syndrome".
The Lancet, Mar. 12, 1988, p. 592 "Nicotine Gum & Haloperidol in Tourette's Syndrome".
The Lancet, vol.. 342, Jul. 17, 1993, p. 182 "Transdermal nicotine patch . . . in Tourette's Syndrome".
Sanberg, et al.; Biomed & Pharmacother., 43 (1989) 19-23 "Nicotine . . . with Tourette's Syndrome".
McConville et al.; Amer. J. Psychiatry 148:6, Jun. 1991, p. 793 "Nicotine . . . in Tourette's Syndrome".
Emerivch et al.; Pharm. Biochem. & Bevhav. vol. 38 (1991), pp. 875-880 "Nicotine . . . Locomotor Hypoactivity".
Emerich, et al.; Psychopharm. Bulletin. vol. 27:3 (1991), pp. 385-390 "Nicotine . . . of Haloperidol".
McConville, et al.; Biol. Psychiatry vol. 31 (1992) pp. 832-840 The Effects . . . in Tourette's Disorder.
Sanberg, et al.; Pharmacol. Biochem & Behavior vol. 46 (1993) pp. 303-307 Nicotine . . . Striatal Mechanisms.
Silver, et al.; J. Amer. Child & Adolesc. Psych. vol. 35 (12) (1996) pp. 1631-1636 "Case Study . . . In Tourette's Syndrome".
Shytle, et al.; Tourette Syn. Assoc. Summer 1997, 25(1): 1,3,7 Researchers Exploring . . . TS Treatment.
Schonenberger, et al.; Helvetica Chimica Acta, vol. 69 (1986) pp. 283-287 "Preparation of Optically Active . . .".
Hsu, Walter; HAVMA, vol. 176, No. 10 (May 1980), pp. 1166-69 "Toxicity and Drug Interactions of Levamisole".
Ballivet, et al.; JMB, 2296, Academic Press Limited, pp. 261-269 "Nicotine Acetylcholine . . . elegans" (1996).
Banerjee, et al.; Biochemical Pharmacology vol. 40, No. 9, pp. 2105-2110, 1990 "[3H] Mecamylamine Binding to Rat Brain Membranes".
Bianchi & Tomasi; Pharmacology 10:226-237, 1973 "Central Nervous System . . . Standard Anti-Parkinson Drugs".
Rupniak et al.; Brit. J. Pharmacol. 1994, 113(4): 1487-1493 "Antinociceptive and Toxic Effects . . . Attributable to Nicotinic Agonist Activity".
Sanberg Paul R.
Shytle Roland D.
Silver Archie A.
Jordan Kimberly
Luther Barbara J.
University of South Florida
LandOfFree
Nicotine antagonists for nicotine-responsive neuropsychiatric di does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nicotine antagonists for nicotine-responsive neuropsychiatric di, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nicotine antagonists for nicotine-responsive neuropsychiatric di will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-363288